Drukker Micha, Benvenisty Nissim
Department of Genetics, Silberman Institute of Life Sciences, The Hebrew University, 91904 Jerusalem, Israel.
Trends Biotechnol. 2004 Mar;22(3):136-41. doi: 10.1016/j.tibtech.2004.01.003.
Human embryonic stem cells have excellent potential for being the ultimate source of transplantable cells for many different tissues. To enable their clinical use, differentiation protocols should be developed and safety standards must be met. The cells should improve symptoms without generating side effects and their immune rejection must be overcome. Profiling of the immune antigens expressed on the cells has revealed that upon differentiation the cells express molecules of the major histocompatibility complex. Here, we propose ways of overcoming the rejection of human embryonic stem cells after transplantation.
人类胚胎干细胞极有可能成为许多不同组织可移植细胞的最终来源。为了使其能够用于临床，需要制定分化方案并满足安全标准。这些细胞应改善症状而不产生副作用，并且必须克服其免疫排斥反应。对细胞表面表达的免疫抗原进行分析后发现，细胞分化后会表达主要组织相容性复合体的分子。在此，我们提出克服人类胚胎干细胞移植后排斥反应的方法。
